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HeartRanolazine, an anti-anginal drug, is a late Na+ channel current blocker that is also believed to attenuate fatty
acid oxidation and mitochondrial respiratory complex I activity, especially during ischemia. In this study, we
investigated if ranolazine's protective effect against cardiac ischemia/reperfusion (IR) injury is mediated at
the mitochondrial level and speciﬁcally if respiratory complex I (NADH Ubiquinone oxidoreductase) function
is protected. We treated isolated and perfused guinea pig hearts with ranolazine just before 30 min ischemia
and then isolated cardiac mitochondria at the end of 30 min ischemia and/or 30 min ischemia followed by
10 min reperfusion. We utilized spectrophotometric and histochemical techniques to assay complex I activ-
ity, Western blot analysis for complex I subunit NDUFA9, electron paramagnetic resonance for activity of
complex I Fe–S clusters, enzyme linked immuno sorbent assay (ELISA) for determination of protein acetyla-
tion, native gel histochemical staining for respiratory supercomplex assemblies, and high pressure liquid
chromatography for cardiolipin integrity; cardiac function was measured during IR. Ranolazine treated hearts
showed higher complex I activity and greater detectable complex I protein levels compared to untreated IR
hearts. Ranolazine treatment also led to more normalized electron transfer via Fe–S centers, supercomplex
assembly and cardiolipin integrity. These improvements in complex I structure and function with ranolazine
were associated with improved cardiac function after IR. However, these protective effects of ranolazine are
not mediated by a direct action on mitochondria, but rather indirectly via cytosolic mechanisms that lead to
less oxidation and better structural integrity of complex I.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
It is now evident that mitochondria play an important role in
mediating both protection and damage during cardiac ischemia
reperfusion (IR) injury. An important target for protection is mito-
chondrial complex I (NADH-Ubiquinone oxidoreductase) [1,2]. Com-
plex I is a large, multi-subunit, integral membrane protein highly
susceptible to functional and structural damage during IR injury
[3,4]. Complex I is bound by cardiolipin, a highly unsaturated fatty
acid lipid in the inner mitochondrial membrane (IMM). Cardiolipin
is essential for maintaining functional and structural integrity of the
respiratory complexes and to assure efﬁcient transfer of electronsBiophys J 98:2068.pos, 2010;
phys J 100:2500.pos, 2011.
Plank Rd, Medical College of
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rights reserved.(e−) within subunits of the complexes and between the complexes
[5]. The transfer of e− via sequential oxidation–reduction of Fe in
the seven Fe–S clusters of complex I exempliﬁes this critical role of
cardiolipin [6,7]. Because cardiolipin is susceptible to oxidative attack
by reactive O2 species (ROS) [8,9] leading to peroxidation and carbon
chain breakdown [10], the assemblies of the respiratory complexes
are also dependent on integrity of cardiolipin.
Ranolazine (Ran) is a clinically used drug known to reduce cardiac
dysrhythmias [11-15] and tissue damage after IR [16]. During IR inju-
ry, Na+ can slowly enter myocytes during phase 3 of the action
potential to initiate dysrhythmias [11]; thus as a late Na+ channel
current blocker [13], Ran is believed to protect hearts by reducing
the incidence of dysrhythmias during IR injury. However, since Ran
prevents intracellular Na+ loading, particularly during IR, it could
also decrease cytosolic Ca2+ overload via Na+/Ca2+ exchange
(NCE) and consequently decrease mitochondrial Ca2+ (m[Ca2+])
overload [17]; m[Ca2+] overload is thought to cause increased pro-
duction of ROS and to trigger cell apoptosis by release of cytochrome
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by Ran against cardiac tissue damage during IR.
Indeed, in a recent isolated heart study of IR injury [18] we
found that Ran treatment just before ischemia reduced cytosolic and
m[Ca2+] loading and ROS emission and, in isolated mitochondria,
reduced cytochrome c release and slightly delayed opening of the
mitochondrial permeability transition pore (mPTP) during cardiac
IR injury. Other reports suggest that Ran exerts a cardioprotective
effect by switching substrate utilization from fatty acids to glucose
metabolism [16,19,20], which reduces mitochondrial O2 demand
and that Ran partially blocks respiratory complex I activity [21].
Although these prior studies give insight into Ran's mode of cardio-
protection, there is no direct evidence that Ran actually attenuates
mitochondrial dysfunction during IR injury
Given the role of complex I in generating ROS during IR [4,22] and
the crucial role of cardiolipin [4,10,22,23] in promoting efﬁcient e−
transfer, we sought ﬁrst to assess changes in many markers of com-
plex I function during IR injury and second to determine if there
were any direct beneﬁcial biophysical and biochemical effects of
Ran on complex I during IR. Because it was unclear if Ran directly tar-
gets mitochondria to protect against IR injury, we hypothesized that
Ran, when present during ischemia, preserves cardiolipin and super-
complex assembly integrity, and especially complex I activity, by its
direct effect to reduce ROS emission and oxidation of mitochondrial
components as a primary mechanism to protect against cardiac IR
injury; alternatively, Ran has indirect effects to restore complex I
function.
2. Materials and methods
2.1. Isolated heart preparation and functional assessment
The Institutional Animal Care and Usage Committee of the Medical
College of Wisconsin approved all animal studies. Guinea pig hearts
(n=43) were isolated and prepared for constant pressure perfusion
studies as previously published [2,24-26]. Brieﬂy, animals were injected
i.p. with 10 mg/kg ketamine to induce anesthesia and with 5000 units
heparin to prevent coagulation. Following decapitation and thoracotomy,
hearts were removed and perfused with Krebs-Ringer's buffer (KR) (in
mM 138 Na+, 4.5 K+, 1.2 Mg2+, 2.5 Ca2+, 134 Cl−, 15 HCO3−, 1.2
H2PO4−, 11.5 glucose, 2 pyruvate, 16 mannitol, 0.05 EDTA and 5 U/L
insulin) gassed with 3% CO2, 97% O2 at pH 7.4 and 37 °C. A saline ﬁlled
balloon catheter attached to a transducer was used to measure left
ventricular pressure (LVP). Diastolic LVP was set initially to zero in
order to monitor any increase as an indicator of diastolic contracture, a
marker of ischemic injury. Coronary ﬂow was measured using an
ultrasonic ﬂowmeter (model T106X, Transonic Systems) placed directly
into the aortic inﬂow line. Spontaneous heart rate was monitored using
bipolar electrodes placed on the right atrial and ventricular walls.
2.2. Protocols for isolated, perfused heart
Given that IR injury is time dependent [27-29], we used an experi-
mental protocol of 30 min of ischemia followed by 10 min reperfusion
to assess changes in complex I. Once heart rate and LVP had stabilized
each heart was subjected to one of the following six protocols: 60 min
of control perfusion (TC) (n=8); 30 min global ischemia (I30) (n=8);
30 min global ischemia followed by 10 min of reperfusion (IR) (n=8);
10 μM Ran given 1 min prior to 30 min global ischemia (RanI30)
(n=8); 10 μM Ran given 1 min before 30 min global ischemia followed
by 10 min reperfusion (RanIR) (n=8), and 10 μM Ran given for 1 min
followed by 40 min of KR perfusion (RanTC) (n=3). At the end of each
experiment, some hearts were immediately immersed into liquid N2 for
later assessment of changes in electron paramagnetic resonance (EPR)
signals, or for later determination of cardiolipin integrity by high pressure
liquid chromatography (HPLC); alternativelymitochondriawere isolated,as described below, for Western blot, analysis of supercomplex assem-
blies, and assessment of complex I activity (NADH oxidation).
2.3. Isolation of mitochondria
At the conclusion of each protocol, some hearts were immediately
removed from the perfusion apparatus and mitochondria were isolat-
ed as previously described [30,31]. In brief, ventricles were excised,
placed in isolation buffer (in mM: 200 mannitol, 5 KH2PO4, 5 MOPS,
1 EGTA, 0.1% BSA and 0.5 mg/ml butylated hydroxy toluene as an
anti-oxidant (pH adjusted to 7.15 with KOH)), and minced into ﬁne
pieces. The suspension was homogenized for 30 s in 2.5 ml isolation
buffer containing 5 U/ml protease (Bacillus licheniformis, Sigma) and
for another 1 min after adding 17 ml isolation buffer. The suspension
was centrifuged at 8000 g for 10 min. The pellet was re-suspended in
25 ml isolation buffer and centrifuged at 750 g for 10 min, the super-
natant was centrifuged again at 8000 g for 10 min, and the ﬁnal pellet,
enriched in mitochondria, was re-suspended in 0.5 ml isolation buffer
and stored at −80 °C until further use.
2.4. Assessment of mitochondrial complex I activity
Mitochondria isolated as described above were centrifuged at
10,000 g and the pellet was re-suspended and washed in hypotonic
buffer containing 25 mM potassium phosphate buffer with 5 mM
MgCl2 at pH 7.2 by centrifugation at 10,000 g. After dilution to the
appropriate concentration, mitochondria were subjected to three
rounds of freeze–thaw cycles in the same hypotonic buffer. The frac-
tured mitochondria were used for assay of dynamic respiratory com-
plex I activity using a cuvette-based spectrophotometer (PTI-model
QM-8, Photon Technology International). The spectrophotometer
was conﬁgured for measuring transmittance and used speciﬁcally to
derive the kinetic proﬁle of complex I activity over time.
Complex I activity was measured by monitoring the dynamic
change in transmittance from oxidation of NADH to NAD+ at
340 nm in a pH 7.2 buffer containing 25 mM potassium phosphate
buffer with 5 mM MgCl2, 2 mM KCN, 2.5 mg/ml BSA, 0.13 mM
NADH, and 65 μM ubiquinone (UQ10) in a total volume of 1 ml [32].
Brieﬂy, after a 3 min baseline measurement, 5 μg of the mitochondrial
lysate was added and transmittance was recorded continuously for
another 5 min; this was followed by transmittance recorded for
3 min after the addition of 2 μg rotenone to completely block complex
I activity. The rate of transmittance after adding rotenone was sub-
tracted from the initial rate of change in transmittance, due to addi-
tion of mitochondria, to obtain rotenone sensitive activity. The rates
of enzyme activity of all groups were normalized to citrate synthase
activity to account for difference in active enzyme at the time of iso-
lation. Rate of activity was calculated using the extinction coefﬁcient
of NADH, 6.81 mM−1 cm−1 with slopes derived over the period
between 200 and 260 s (ﬁrst order rate kinetics) [32].
2.5. Histochemical staining of complex I
The amount of total complex I and activity was also determined
using histochemical staining. First, freshly isolated mitochondria were
disrupted using the method of Schägger et al. [35]. Brieﬂy, 400 μg of
pelleted mitochondria were re-suspended in pH 7.0 buffer containing
in mM: 50 NaCl, 50 imidazole/HCl, 2 6-aminohexanoic acid, and 1
EDTA. Next mitochondria were solubilized by adding dodecylmaltoside
(2.5 g/g) and digitonin (6.0 g/g), followed by incubation on ice for
10 min and centrifugation at 16,000 g for 30 min. Then the supernatant
was retained and 5 μl of 50% glycerol was added. Gradient gelswith a 4–
13% polyacrylamide gradient were used for separation of respiratory
complexes using 25 mM imidazole anode buffer and 50mM tricine,
7.5 mM imidazole cathode buffer. Gels were then used for histochemi-
cal staining to assess mitochondrial complex I amount and activity, by
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Blue Tetrazolium chloride (NBT) and 2.5 mg/ml NADH. Bands were vis-
ible after 5 min incubation. The gels were transferred into Tris–HCl at
pH 7.4 and scanned for densitometry. Individual band densities were
normalized to their total respective lane Coomassie stain intensities.
2.6. Determination of supercomplex assemblies
Mitochondrial respiratory complexes are integrated into multi-
complex assemblies that can be detected using native gel electropho-
resis [33,34] with the use of mild detergents to solubilize the mito-
chondrial membranes while preserving both the functional and
structural integrity of the complexes. Mitochondria were prepared
as described for histochemical staining for complex I activity, except
that 6.0 g/g digitonin, and no DDM, was used for solubilization of
mitochondria and retaining supercomplex assemblies [36]. Proteins
were then separated as described above in a 3–13% polyacrylamide
gradient gel, and used for either Coomassie staining or histochemical
staining of respiratory complexes.
For Coomassie staining, gels were stained for 20 min in 0.2%
Brilliant Blue G in methanol:acetic acid:water (MAW) (40:7:53 v/v),
and later destained with MAW. After destaining, the gels were
scanned using a desktop scanner (CanoScan 8400F) and densitometry
was performed using the ImageJ program (National Institutes of
Health, Bethesda, MD). Respiratory complex I function was detected
as in Section 2.5. Complexes III and IV functions were determined
by incubating the gels in 50 mM sodium phosphate buffer at pH 7.2
containing 5 mM cytochrome c and 0.5 mg/ml diaminobenzidine
[36]. Histochemical staining of complexes III and IV was performed
to determine supercomplex components. The observed band intensi-
ties were normalized against total lane Coomassie stain intensities.
The components of supercomplexes were further determined by
2nd dimension SDS-PAGE. Brieﬂy, supercomplex bands positive for
complexes I, III and IV were excised from the gel and incubated in
1% SDS and 1% β-mercaptoethanol for 1 h at room temperature. The
bands were then placed in lanes of a 10% polyacrylamide gel and elec-
trophoresed in Tris-Glycine-SDS buffer for 1.5 h at 125 V. The proteins
were then transferred onto PVDF membranes and used for Western
blots using a cocktail of antibodies (Invitrogen, CA) against the fol-
lowing proteins: complex I subunit ND6, complex II FeS subunit, com-
plex III core 2, complex IV subunit I, and complex V subunit ∝.
2.7. Western blot detection of complex I
Complex I subunit NDUFA9 is an integral membrane subunit
reported to be more prone to post translational modiﬁcations (PTM)
than other subunits [37,38]. Hence any change in levels of this subunit
indicates compromised membrane integrity and possibly PTM of the
subunit.Mitochondrial protein (50 μg)was solubilized in Laemmli buff-
er and resolved using sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) as described by Laemmli [39] and transferred
onto poly vinilidine diﬂuoride membranes using Transblot System
(Bio-Rad, Carlsbad, CA) in 50 mMtricine and 7.5 mM imidazole transfer
buffer. Membranes were blocked with 10% non fat dry milk in Tris
Buffered Saline—TBSt (25 mM Tris–HCl at pH 7.5, 50 mM NaCl and
0.1% Tween 20) by incubating for 1 h followed by incubation in anti-
NDUFA9 antibody (Invitrogen, CA) solution overnight at 4 °C. After
threewasheswith TBSt themembranewas incubatedwith an appropri-
ate secondary antibody conjugated to horse-radish peroxidase for 3 h.
After ﬁve washes with TBSt the membrane was incubated in enhanced
chemiluminescence detection solution (ECL-Plus, GE-Amersham) and
exposed to X-ray ﬁlm for autoradiography. Equivalent protein loading
was conﬁrmed using an antibody against cytochrome c oxidase (com-
plex IV) subunit 1 (Invitrogen, CA) since complex IV is relatively more
resistant to IR injury than is complex I at 10 min reperfusion [27-29].2.8. Acetylation of mitochondrial protein
A common PTM is acetylation. Total mitochondrial protein acety-
lation was analyzed using Enzyme Linked Immuno Sorbent Assay
(ELISA). Mitochondria, isolated as described above, were solubilized
by suspension in phosphate buffered saline, pH 7.4, by the addition
of 0.5% Tween-20. 20 μg of the lysed protein was suspended in 50 μl
of sodium carbonate-bicarbonate buffer, pH 7.4 and coated overnight
in a 96 well plate. The wells were washed with PBS and blocked with
1% BSA. After three washes, anti-acetyl lysine antibody was added to
each well. Following a three-hour incubation, the wells were washed
again in PBS, and incubated with appropriate secondary antibody.
Color development was achieved by the use of a solution containing
o-phenyline diamine, citric acid, and H2O2. The plate was scanned
for changes in optical density at 490 nm [40].
2.9. Electron paramagnetic resonance
An EPR system (Elexsys E500 Pulse EPR spectrometer, Bruker, Biller-
ica, MA) was used to detect the transfer of e− through respiratory com-
plexes I and II (succinate dehydrogenase) resulting from the successive
oxidation/reduction of Fe in Fe–S clusters. Some treated or untreated iso-
lated hearts (n=4 per group)were immediately transferred to liquid N2
at the end of the protocol and ground to a ﬁne powder. The powder was
transferred into quartz glass tubes which were stored at −80 °C until
analysis. EPR signals were obtained by scanning the samples in a high
intensity magnetic ﬁeld (3000–4000 G) at 10 Kelvin, 9.6 GHz, 5 mW
microwave power and 5 G amplitude modulation. Each sample was
scanned 9 times and spectra were averaged [41,42]. Signal intensities
were measured for g's of 2.023 (3Fe–4S attributed to cluster S3 of com-
plex II, or to mitochondrial aconitase), 2.006 (attributed to semi-
ubiquinone radical, UQ•), 1.94 (2Fe–2S attributed to N1b of complex I,
or to S1 of complex II), and 1.89 (4Fe–4S attributed to N4 of complex I,
or to the Rieske center of complex III) [43].
2.10. Isolation and analysis of cardiolipin by HPLC
The integrity of cardiolipin isolated from minced heart tissue was
assessed using HPLC (System Gold, Beckman Coulter, Fullerton, CA).
HPLC detects difference in molecular weight, and thus different spe-
cies, by the change in mobility of individual molecules through the
HPLC column. Lipids were extracted from hearts using a modiﬁed
method of Hara et al. [44]. Brieﬂy, hearts were removed from the per-
fusion system after treatments and quickly frozen in liquid N2 and
ground to a ﬁne powder. Approximately 1 g of powdered tissue was
added to 18 ml hexane:isopropanol (3:2) and mixed for 1 min. The
suspension was ﬁltered through Whatman no. 5 ﬁlter paper. The
powdered tissue was washed twice with 2 ml hexane:isopropanol.
Isolated lipids were then analyzed and estimated for cardiolipin con-
tent using thin layer chromatography (TLC). Brieﬂy, 200 μl of each
sample was loaded onto a Whatman silica gel-60 TLC plate and
allowed to dry; 50 μg of puriﬁed bovine heart cardiolipin was used
as the standard. Lipids were separated using chloroform:methanol:
acetic acid:water (55:37.5:3:2) [45]. Bands were visualized by expo-
sure to iodine vapors for 5 min. The ratio of band intensity for each
group's cardiolipin was estimated and total lipids in each fraction
were calculated. Appropriate amount of lipids equivalent to 200 μg
of cardiolipin was dried under N2 gas and resuspended in 20 μl hex-
ane:isopropanol (3:2) and then injected into the HPLC. HPLC analysis
was performed using the method of Barcelo-Coblijn et al. [45] at
208 nm.
2.11. Statistical evaluation of data
For the intact heart studies, measurements for each group were
compared at baseline, during the brief treatment with or without
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For all other studies, measurements for each group were measured
at the end of the protocol. All data are expressed as mean±SEM.
Between groups and within group individual values were subject to
two-way analysis of variance to determine overall signiﬁcance. If F
values were signiﬁcant (pb0.05), post hoc comparisons of means
tests (Student–Newman–Keuls) were used to compare the groups
within each subset. In mitochondrial studies, statistical analysis was
performed similarly. Differences between means were considered
signiﬁcant when pb0.05 (two-tailed).
3. Results
3.1. Spectrophotometric determination of complex I activity
Representative kinetic traces of complex I activity, monitored in a
spectrophotometer as the rate of oxidation of NADH to NAD+ in the
presence of UQ10, illustrate differences dependent on the treatment
(Fig. 1A). In summarized data from 4 hearts from each of the 5 exper-
imental groups (Fig. 1B) controls (TC) exhibited a NADH oxidationFig. 1. A: Representative spectrophotometric assay of mitochondrial complex I activity du
enzyme and the inhibitor. B: Summary data shows ischemia alone reduced the activity of the
the decrease in activity, but this was not as pronounced as with ranolazine (Ran) on reperfu
and normalized to citrate synthase levels. * indicates pb0.05 for I30/IR vs. TC; # indicates prate of 122±5 nmol/min/mg protein with a large decrease in oxida-
tion rate after I30 to 49±8 nmol/min/mg, but partial restoration to
106±1 nmol/min/mg in the RanI30 group. Similarly, there was a
large decrease in complex I activity after IR to 70±4 nmol/min/mg,
which was completely restored to 123±7 nmol/min/mg in the
RanIR group. No changes in complex I activity were observed in the
RanTC group (data not shown). To determine if Ran directly alters
mitochondrial complex I activity in fractured mitochondria, in pre-
liminary experiments Ran was added to freeze–thaw fractured mito-
chondria from the TC, I30 and IR groups, followed by measurement of
complex I activity; the result was a slight but insigniﬁcant decrease in
activity (data not shown).
3.2. Histochemical staining for complex I function in gel
A representative gel (Fig. 2, upper panel) for NBT-oxidoreductase
activity, reﬂecting complex I function with or without IR and Ran,
illustrates decreased band density after I30 and IR but a higher band
density after RanI30. Summary data (Fig. 2, lower panel) showed
that band density decreased after I30 (94±2%) and IR (96±1%)ring cardiac ischemia reperfusion depicting the time points of addition of substrate,
enzyme, which was restored by treatment with ranolazine. Reperfusion itself corrected
sion. Note that the activities depicted in B have been corrected for rotenone sensitivity
b0.05 for RanI30/RanIR vs. I30/IR.
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ischemia resulted in a signiﬁcantly higher band density for RanI30
(105±1%) vs. I30 alone, whereas band density for RanIR (110±4%)
was not signiﬁcantly greater than that for IR alone. The observed
band densities were normalized to the total lane intensities.3.3. Supercomplex assemblies detected by native gels
A representative image of a native gel (Fig. 3, panel A) stained by
Coomassie Brilliant Blue illustrates supercomplexes—SC1 and SC2
comprised of complexes I, III and IV as identiﬁed by histochemical
staining for complexes I (panel B) and III and IV (panel C), and respi-
ratory complexes after 2D electrophoresis detected by Western blot
using antibodies against the indicated subunits (panel D). The two
supercomplexes presumably are composed of multiple copies of
respiratory complexes. Summary data of supercomplex assemblies
from Coomassie stained gels (Fig. 3E) showed that band intensity
for the supercomplex SC1 (TC=100%) was lower in I30 (86±1%),
IR (88±1%) and RanI30 (87±2%). Ranolazine treatment improved
the band intensity of SC1 following IR (96±1%). Band intensity for
supercomplex SC2 showed similar results. Compared to TC (100%),
there was a signiﬁcant decrease in band intensity in I30 (77±5%)
and IR (85±2%). Ranolazine treatment improved band intensity fol-
lowing I30 (RanI30=93±1%) and IR (RanIR=95±5%). Complex I
was not found to associate further with complexes II and V to form
other supercomplexes (data not shown). The observed band densities
were normalized to the total lane intensities.3.4. Determination of integrity of complex I subunit NDUFA9 by Western
blots
A representative blot for the complex I subunit NDUFA9 (Fig. 4,
upper panel) from hearts subjected to IR±Ran illustrates decreased
intensity after I30 and restoration after RanI30 and RanIR. Complex
IV subunit I was used as the loading control. Summary data (Fig. 4,
lower panel) showed that compared to TC (100%) the anti-NDUFA9
immune reactive band intensity was signiﬁcantly lower after I30
(84±9%) but was restored after RanI30 (109±7%). Band densities
for IR (101±4%) and RanIR (112±7%) groups were not different
from the TC group.Fig. 2. Upper panel: Representative histochemical gel staining of complex I activity,
measured as NBT-oxidoreductase, during cardiac ischemia reperfusion. Lower panel:
Summary data shows that ischemia alone resulted in lower staining than in time con-
trols and reperfusion. Ran treatment increased staining, indicating improved complex I
function. * indicates pb0.05 for I30/IR vs. TC; # indicates pb0.05 for RanI30/RanIR vs.
I30/IR.3.5. Analysis of acetylation of mitochondrial proteins using ELISA
The optical density for acetylated mitochondrial proteins, as
detected by ELISA, showed an overall decrease in all groups compared
to TC (76±4.9 arb. units) (data not represented graphically). I30
showed the least acetylation (41.7±3.1 arb. units), whereas IR
partially restored the acetylation (57.8±4.6 arb. units). Treatment
with Ran partially restored acetylation in both groups (Ran I30=
56.5±2.7 arb. units; RanIR=59.8±2.3 arb. units). Values for each
treatment group were signiﬁcantly lower than the TC group, and
there was a statistically signiﬁcant difference (pb0.05) between
I30 and RanI30, but not between IR and RanIR groups.
3.6. Electron transfer in Fe–S clusters by electron paramagnetic
resonance
Averaged peak intensities (4 hearts per group) of Fe–S resonance
signals (in arb. units) showed differences in peak signals dependent
on the treatments (Fig. 5A). The g=2.023 signal was assigned to S3,
the 3Fe–4S cluster of complex II, or to mitochondrial aconitase,
g=2.006 to the semi-ubiquinone radical (UQ•), g=1.94 to cluster
N1b of complex I, or to cluster SI of complex II, and g=1.89 to cluster
N4 of complex I, or to the Rieske center of complex III. Summary data
(Fig. 5B) showed that compared to TC (3.1±1.4 arb. units), neither
I30 (2.7±0.8) nor IR (4.2±0.6) signiﬁcantly altered the g=2.023
signal. However, Ran treatment reduced the g=2.023 signal further
after RanI30 (1.6±0.4), but not after RanIR (4.2±1.0). There was a
signiﬁcant increase in the g=2.006 radical after I30 (1.49±0.07),
which was lower in TC (0.87±0.09) and after IR (1.06±0.03). Ran
treatment also reduced the g=2.006 signal (RanI30=1.29±0.09;
RanIR=1.02±0.04). There was also a signiﬁcant increase in signals
pertaining to g=1.94 and 1.89 during ischemia, which returned to
TC levels after reperfusion. The contribution at g=1.94 for N4 was
veriﬁed by the changes noted at g=1.89; i.e. the contribution of
N1b and S1 can be estimated after evaluating the contribution of
N4. The signal at g=1.94, contributed by N3, was small as estimated
by the weak signal at g=1.86, the low ﬁeld g-value for the signal
from N3. Similarly the contribution to the signal at g=1.92 from N2
was weak as determined by the absence of signal from the low ﬁeld
g-value for N2 at 2.05.
3.7. Determination of cardiolipin integrity by HPLC
Representative HPLC traces of cardiolipin integrity were different
depending on treatment (Fig. 6A). Compared to the cardiolipin stan-
dard TC (93±2 arb. units), there were signiﬁcant decreases in the
areas under the curves in I30 (56±21 arb. units) and more so in IR
(32±12 arb. units) groups, reﬂective of damaged cardiolipin. In sum-
mary data (Fig. 6B) the RanI30 group (49±15 arb. units) showed no
improvement over the I30 group alone, but the RanIR (69±8 arb.
units) group showed a larger area under the peak that is reﬂective
of less fragmented cardiolipin. The number of peaks as detected by
HPLC was also higher (reﬂecting more fragmented species) in I30
and IR groups than in RanI30 and RanIR groups, respectively (Fig. 6A).
3.8. Improved cardiac function after IR injury with ranolazine
Heart rate, coronary ﬂow, diastolic LVP, and developed (systolic-
diastolic) LVP remained unchanged during continuous perfusion of
hearts for 60 min (TC, data not displayed) after which time hearts
were harvested for examination of complex I function using the
methods described above. At the end of 30 min no ﬂow global ische-
mia, there was no heart beat and diastolic LVP was elevated (Table 1);
after 10 min reperfusion heart rate and coronary ﬂow were similar to
those of the TC in all IR groups. On the other hand, diastolic LVP was
more elevated in the IR group than in the RanIR group and developed
Fig. 3. Determination of supercomplex assemblies using native PAGE. Panel A: Coomassie stained gel after native PAGE. SC1 (patterned) and SC2 (ﬁlled) indicate supercomplexes
composed of complexes I, III and IV, with varying copies of each complex. Components of supercomplex determined by histochemical staining for complex I (panel B), complexes III
and IV (panel C) and by Western blot analysis of SC1 and SC2 against respiratory complex subunits (panel D). Summary data of supercomplex assemblies from Coomassie stained
gels (panel E) shows reduction in supercomplex assemblies following ischemia and reperfusion, and restoration by ranolazine treatment. * indicates pb0.05 for I30/IR vs. TC; #
indicates pb0.05 for RanI30/RanIR vs. I30/IR.
424 A.K. Gadicherla et al. / Biochimica et Biophysica Acta 1817 (2012) 419–429LVP was more depressed in the IR group than in the RanIR group.
These data indicate that Ran had a protective effect on reducing con-
tracture during ischemia and on increasing contractile function onFig. 4. Upper panel: Representative Western blot detection of complex I subunit
NDUFA9 during cardiac ischemia reperfusion. Lower panel: Summary data shows
that ischemia reduced the amount of detectable subunit, indicating a loss of protein
or protein damage. Both reperfusion and Ran treatment during ischemia restored pro-
tein levels to time control levels. * indicates pb0.05 for I30/IR vs. TC; # indicates pb0.05
for RanI30/RanIR vs. I30/IR.reperfusion. These protective effects were associated with improve-
ments in several assays of complex I function and the integrity of its
support structure, cardiolipin.
4. Discussion
4.1. Summary of ﬁndings
Complex I is a major source and target of ROS during IR [4,28] and
excess ROS is a major determinant of poor return of cardiac function
after IR injury [2,25]. For that reason we used several experimental
tools to search for deleterious biochemical and biophysical changes
in respiratory complex I function and structural integrity in hearts
subjected to 30 min ischemia alone, or to 30 min ischemia plus
10 min reperfusion. Ran, which is reported to have cardio-protective
effects [11,12,14,15] by switching substrate preference, among other
proposed effects [16], was examined for its potential to attenuate
damage to complex I and to improve cardiac function when present
during ischemia.
We found that ischemia alone a) reduced the rate of NADH oxida-
tion, b) reduced protein acetylation, c) decreased complex I function,
d) reduced supercomplex assembly, e) decreased the detection of a
complex I subunit, f) increased the reduced state several fold in
three distinct Fe–S clusters in complex I and/or complex II [2Fe–2S
in N1b and/or S1 and the 4Fe–4S cluster N4, and in complex I N4
and/or Rieske center in complex III], increased the signal at 2.006
Fig. 5. A: Representative traces of EPR signals during cardiac ischemia reperfusion denoting changes in three mitochondrial Fe–S clusters and semiubiquinone. B: Summary data
shows the changes in spectral magnitudes of the Fe–S clusters and semiubiquinone. Ischemia increased electron transfer within complex I and semiubiquinone; this was reversed
on reperfusion. Ran had a small effect to decrease electron transfer during reperfusion. I, II, III = respiratory complexes; N and Rieske = FeS clusters. * indicates pb0.05 for I30/IR vs.
TC; # indicates pb0.05 for RanI30/RanIR vs. I30/IR.
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aconitase] and, g) reduced the structural integrity of cardiolipin,
a supporting structure for mitochondrial complexes. Compared to
ischemia alone, treatment with Ran during ischemia resulted in full
or partial restoration of: a) the rate of NADH oxidation, b) the acety-
lation of mitochondrial proteins, c) the detection of complex I subu-
nit, and d) the supercomplex assembly.
During the short 10 min reperfusion period, complex I dysfunction
persisted, acetylation levels remained lower, and cardiolipin showed
greater disintegration. Because the expression levels of respiratory
complex I subunits are not likely to change given the short time peri-
od of our protocols, any reduction in complex I subunit band intensity
probably reﬂects compromised integrity of the subunit's structure.
The reduction in NADH oxidation rate with reperfusion alone was
reversed and cardiolipin integrity was improved by Ran treatment.Electron transfer through N1b of complex I and/or SI of complex II
was improved by Ran on reperfusion and through N4 of complex I
or the Rieske center of complex III. Each of these changes observed
after Ran treatment was associated with improved diastolic LVP dur-
ing ischemia and improved contractile function during reperfusion.
However, Ran did not alter complex I activity when applied directly
to fragmented mitochondria in either the TC, I30, or IR groups.
Our study supports our alternative hypothesis that Ran treatment
indirectly leads to partial protection of mitochondria, as shown in
part, by improved complex I activity, restored e− transfer through
some Fe–S clusters, and retained supercomplex assembly and cardio-
lipin integrity. This range of protection implies that Ran is not likely
to have a direct molecular interaction with complex I, which is sub-
stantiated by our preliminary ﬁnding that Ran had no effect on com-
plex I activity when added directly to fractured mitochondria. Hence
Fig. 6. A: Representative traces of cardiolipin integrity by HPLC analysis during cardiac ischemia reperfusion. B: Summary data shows that ischemia alone reduced the area under the
major peak of cardiolipin, and reperfusion decreased it further. The additional peaks seen in the spectra could be modiﬁed/breakdown products of cardiolipin. Treatment with rano-
lazine (Ran) restored peak heights and also decreased the number of peaks, indicating that Ran treatment preserves cardiolipin. * indicates pb0.05 for I30/IR vs. TC; # indicates
pb0.05 for RanI30/RanIR vs. I30/IR.
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to mitochondrial structure. We propose that by maintaining complex
I e− ﬂow and preserving the supercomplex assemblies, the tendency
for electron leak and subsequent generation of O2•− is reduced. This
notion is supported by our recent observation [18] that by lowering
ROS emission with reduced cytosolic and m[Ca2+] loading, Ran
indiscriminately reduces oxidative damage to complex I and to its
supporting structures (among other mitochondrial and cytosolic mol-
ecules). Our comprehensive examination of complex I function dur-
ing IR injury demonstrates the extent of structural and functional
damage to complex I and the impact of a non-mitochondrial-
targeted drug to indirectly protect mitochondrial function, likely by
reducing ROS emission.
4.2. ROS and damage to respiratory complexes during cardiac injury
Superoxide radicals (O2•−) are produced in small amounts in
mitochondria under O2 and substrate replete conditions, but the
balance between O2•− generation and free radical scavenging (ROSemission), is altered in high oxidative stress conditions such as IR in-
jury [1,22,46,47]. These O2•− radicals and their downstream products
attack all types of cellular macro molecules, i.e. proteins, lipids, carbo-
hydrates, and D(R)NA, thereby altering their structure and function
[48,49]. Although all major biomolecules are susceptible to oxidative
damage, the extent of this damage is dependent on the molecular
structure, the duration of exposure to ROS, the concentration and
kind of ROS, and the capacity of ROS scavengers available.
Respiratory complexes differ in their susceptibility to IR injury.
Complexes I and III are believed to be more susceptible to IR injury
than complexes II, IV, and V [22]. A useful kinetic test for an effect
of Ran to protect respiratory complex I against IR injury is the mea-
sure of catalytic conversion rate of NADH to NAD+ in complex I dur-
ing IR. Although respiratory complexes I and III are reported to be a
major source of O2•− generation [1,3,50,51], many studies have impli-
cated complex I to also be the most susceptible of the respiratory
complexes to ischemic damage [4,52]. Complex I is also a major site
of e− leak during IR; this is likely to drive e− transfer backward
through complex I toward the NADH binding site [2,53,54]. Indeed,
Table 1
Cardiac function before, during and after IR injury.
Baseline Ischemia (30 min) Reperfusion (10 min)
dLVP/dtmax (mm Hg/s)
IR10 2342±228 1342±136
RanIR 2449±133 2406±151#
dLVP/dtmin (mm Hg/s)
IR10 2052±129 955±106
RanIR 1923±185 1971±166#
Systolic-diastolic LVP (mm Hg)
IR10 88±4 38±5
RanIR 90±4 57±7#
Diastolic LVP (mm Hg)
I30 0±0 3±1
RanI30 0±0 1±1#
IR10 0±0 5±2
RanIR 0±0 0±0#
Coronary ﬂow (ml/min)
IR10 15.9±0.7 14.8±0.6
RanIR 15.2±1.1 15.3±1.1
Heart rate (beats/min)
IR10 227±4 228±2
RanIR 233±5 226±2
LVP = Left ventricular pressure.
I30 = 30 min of global ischemia.
IR10 = 30 min of global ischemia+10 min reperfusion.
RanI30 = 10 μM Ran given 1 min before I30.
RanIR = 10 μM Ran given 1 min before IR10.
# Indicates pb0.05 for RanI30 or RanIR vs. I30 or IR10.
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that complex I function was attenuated; this is consistent with the
increased (backward) e- transfer in complex I and the decreased
(forward) e− transfer in complex II [22,55].
Interventions to limit backward e− transfer from complex II into
complex I may be helpful in attenuating ROS release [2,53,56]. Indeed,
we [56] showed previously that amobarbital, a complex I blocker at
the rotenone site, itself slightly enhanced generation of O2•− before is-
chemia but attenuated O2•− emission during IR [2]. Other modulators
of complex I are also known to have protective effects against IR inju-
ry [52]. The decreased rate of NADH oxidation in ischemic hearts,
compared to reperfused hearts, might also be due to a lack of the
e− acceptor O2. When reperfusion begins there is an abrupt avail-
ability of O2, and hence a higher rate of respiratory chain activity.
In support of this, we found faster respiratory complex I activity in
Ran -treated hearts than in the untreated ischemia and IR groups.
4.3. Mechanism of mitochondrial protection by ranolazine during cardiac
IR injury
Ranolazine is a clinically useful anti-anginal drug [15,57] that was
found originally to block the late Na+ current that occurs with ische-
mia [11,58-60]. But others have reported that Ran induces a switch
from the usual substrate preference from fatty acids to glucose, and
that it partially blocks complex I at an unconﬁrmed site, particularly
in uncoupled mitochondria [21]. If Ran were indeed a partial complex
I blocker in vivo as Wyatt et al. [21] reported in in vitro isolated mito-
chondrial experiments, this might contribute to preserving its struc-
ture and function during IR injury as we found. But it is unlikely
that Ran penetrates membranes effectively due to its hydrophilic
structure. It is conceivable that a fat soluble metabolite of Ran is a
direct mitochondrial protective drug, but this will require direct evi-
dence of a metabolite with actions on complexes and other mitochon-
drial targets. Because we found that Ran had no direct effects on
mitochondrial function when applied directly to isolated, energizedmitochondria [18], or to fractured mitochondria, we believe it is
unlikely to directly target complex I or any other mitochondrial pro-
tein and its supporting structures.
During ischemia there is an increase in cytosolic [Na+] due to fail-
ure of the Na+/K+ ATPase pump and an increase in toxic intermedi-
ates [60]. This triggers NCE, which results in increased cell Ca2+
loading, and consequently, m[Ca2+] loading which may lead to mito-
chondrial oxidative damage by “Ca2+-induced ROS release” [46,61].
Increased m[Ca2+] contributes to an increase in ROS emission
under certain circumstances, either by increasing the rate of O2•− gen-
eration or by reducing the rate of ROS scavenging [17,61,62]. There-
fore we postulated that Ran induces its protective effect by reducing
NCE in the cytosolic compartment to reduce Ca2+ loading, and by ex-
tension, to mitigate m[Ca2+] loading. Our conclusion derives from the
principal earlier ﬁnding that Ran is a late Na+ channel current blocker
[11,58-60], and our report that Ran reduces m[Ca2+] overload and
ROS emission during late ischemia and reperfusion [18]. This decrease
in ROS may or may not be a direct consequence of an improved elec-
tron transport chain activity or reduced m[Ca2+] overload. However,
Song et al. [63] reported that Ran attenuated H2O2-induced cytosolic
Ca2+ overload and cardiac contractile dysfunction suggesting that
“ROS induced Ca2+ loading” can be attenuated by Ran.
The oxidative stress that occurs in ischemia is known to activate
deacetylases [64,65], which cause a decrease in lysine acetylation.
Deacetylation can disturb the secondary and tertiary associations
among proteins and/or their subunits. Hence it is possible that by pre-
serving acetylation, a reversible PTM, this might help preserve the
integrity of mitochondrial proteins. Ran treatment attenuated the
lysine deacetylation of mitochondrial proteins during ischemia. If
Ran could access the mitochondrial matrix, it might interfere with
the action of deacetylases to protect the proteins but there is no direct
evidence for this.4.4. Electron transfer in complex I and protective effect of ranolazine
during cardiac IR injury
Changes in EPR spectra can occur due to many factors, including
but not limited to: a loss of one or more Fe–S clusters, a saturated
oxidation or reduction potential, and proximity of neighboring clus-
ters. Complex I subunits with their Fe–S clusters mediate single e−
transfer so any damage to these subunits or Fe–S clusters will cause
disrupted e− transfer. Once an e− enters the Fe–S cluster chain, its
further movement is affected by the redox states of the following
Fe–S clusters [6,66]. From FMN one e− enters a transport chain con-
sisting of one binuclear and the six tetranuclear Fe–S clusters leading
(during forward e- transfer) to the Q10 binding site (FMN→N3→
N1b–N4–N5–N6a–N6b→N2→UQ•→Q10) [73] and ultimately to
complex III. In our study, we observed no signiﬁcant change in the
g=2.023 signal representing the 3Fe–4S cluster, S3, of complex II
with IR. In contrast, Myers et al. [42] reported an increase in the aco-
nitase signal (with the same g value) following oxidative stress with
chromium radicals. There was a signiﬁcant increase in the amount
of the EPR detectable UQ• radical during ischemia, and this was re-
duced by reperfusion as well as by Ran treatment. It should be
noted however, that UQ• is one of the several free radicals generated
during ischemia, so this is not representative of the total oxidative
stress in the tissue.
In contrast to S3 of complex II, there were signiﬁcant increases in
the signal intensities for g=1.94 and 1.89 during ischemia that de-
creased again on reperfusion; this could represent reverse e− transfer
during ischemia within complex I. It is difﬁcult to ascertain the exact
source of this signal because it can emanate from cluster N1b of
complex I or SI of complex II. Although other clusters like the 4Fe–
4S and N3 have a g-value close to 1.94 (1.93 for N3) the complemen-
tary peak (2.04 for N3) is too weak to detect, implying there is little
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nal to N1b and/or S1.
Reverse e− transfer is believed to occur in the respiratory chain
during ischemia, particularly within complex I [54]. Our results sup-
port this assumption. It is plausible from the EPR spectra of N1b
(g=1.94) and N4 (g=1.89) clusters that ischemia can cause a severe
back up of e− to cause reverse e− transfer back in complex I. Reperfu-
sion appeared to largely correct this e− back up, whereas Ran did not
affect signal intensity during ischemia, but increased it on reperfu-
sion. The reason for this is unclear. Similarly, we observed an increase
in signal intensity for g=1.89 during ischemia. Again, this signal can
be attributed to either cluster N4 of complex I or the Rieske center of
complex III; however, since most of this signal was generated by the
N4 cluster (as noticed after spectral splitting at higher resolution),
we conclude that the observed changes were due to cluster N4 and
not to the Rieske center.
The signal at g=2.023, assigned to the oxidized state of the 3Fe–
4S, S3 cluster in complex II decreased with ischemia and fell even
more during 30 min ischemia with Ran, but recovered during reper-
fusion with or without Ran. We attribute the decrease in the 2.023
signal to greater e− ﬂow through complex II, thus reducing the S3
center. This complements the suggestion that there is a reverse e−
transfer during ischemia.
4.5. Cardiolipin integrity and protective effect of ranolazine during
cardiac injury
Cardiolipin, a highly unsaturated fatty acid molecule, is prone to
ROS attack with the most commonly encountered changes being
lipid peroxidation and carbon chain breakdown [49]. The qualitative
mobility of cardiolipin was assessed using HPLC by a change in area
under the peak, compared to the cardiolipin standard, and by the
appearance of secondary peaks with different retention times; these
changes represent distortion of cardiolipin. Moreover, cardiolipin
has a high content of oxidatively sensitive linoleic acid, a phospholip-
id unique to mitochondria. Its location in the IMMmakes it extremely
susceptible to oxidative damage by ROS, whether acutely as in IR
injury or chronically as in aging [8,9]. Cardiolipin is necessary not
only for the assembly of each respiratory complex and the supercom-
plexes, but also for the proper functioning of respiratory complexes
and for that matter an efﬁcient e− transfer. Thus any fragmentation or
damage to cardiolipin structure reﬂects on the performance of the
respiratory complexes [4,5,10]. Indeed, in a pilot study, analysis of the
complex I subunit NDUFS3, which is in the peripheral arm of complex
I [67] showed no changes inWestern blot band intensitywith andwith-
out IR and with and without treatment with Ran (data not shown),
compared to the decrease in band intensity of NDUFA9, which is a
membrane integral subunit. This shows the importance of the integrity
of cardiolipin on maintaining complex I structure and function.
Ran is also reported to partially inhibit fatty acid oxidation [21]
and to stimulate glucose oxidation in hearts during normoxia, ische-
mia, and IR [20,68]. Thus Ran may also act as a metabolic modulator
[19,20] that promotes more efﬁcient use of O2 and substrates. A
reduction in ROS emission would likely reduce oxidative damage to
cardiolipin, as suggested by our HPLC experiments, in which Ran-
treated hearts exhibited a partial restoration toward the control
cardiolipin HPLC spectra. Our data showing restoration of cardiolipin
integrity, along with improvements in complex I structure and activ-
ity in the Ran treated hearts, are consistent with another study show-
ing that restoration of cardiolipin content in mitochondria can
improve complex I activity [4].
5. Conclusions
Protection of hearts against IR injury by Ran is associated with
mitochondrial protection. Although Ran exerts a protective effect oncomplex I and its supporting structures, it is doubtful from our
study that Ran mediates its protection by directly interacting with
complex I, given our ﬁnding that Ran had no direct effect on complex
I activity, or on any other mitochondrial function we measured in
intact or fragmented mitochondria. The reversal or attenuation of
complex I dysfunction, albeit indirect, by Ran points out the impor-
tance of complex I integrity and function as important factors in
restoring cardiac function. Moreover, given the effects we and others
observed, Ran appears to protect hearts in various ways, including but
not limited to blocking the late Na+ current. Concomitant decreases
in m[Ca2+] overload and ROS emission, induced by Ran, are the prob-
able factors that lead to preservation of cardiolipin, maintaining
supercomplex structure and less backward e− transfer through the
Fe–S clusters of complex I, thereby improving its efﬁciency in func-
tion and NADH oxidizing capability. Nevertheless, our study empha-
sizes the extent of injury to complex I and other mitochondrial
structures, and expresses the importance of understanding the mech-
anisms of compounds to protect mitochondria during cardiac IR
injury.Disclosures
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